<DOC>
	<DOC>NCT01920399</DOC>
	<brief_summary>Investigate the safety and tolerability, as well as PK profile of ceftazidime-avibactam (CAZ -AVI) administered in single and repeated intravenous (IV) infusions in healthy Chinese subjects.This study data will be used to support CAZ-AVI NDA in China.</brief_summary>
	<brief_title>A Phase I Study to Assess the Safety, Tolerability and PK of Ceftazidime-Avibactam in Healthy Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Avibactam</mesh_term>
	<mesh_term>Avibactam, ceftazidime drug combination</mesh_term>
	<criteria>Key Provision of signed and dated, written informed consent prior to any studyspecific procedures. Healthy male and female (of nonchild bearing potential) Chinese subjects, with suitable veins for cannulation or repeated venipuncture BMI 19 to 24 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg. Key Any clinical condition requiring the regular use of any medication. Consumption of alcohol, drug, tobacco (cigarettes). Sensitive to any food, or any serious reaction to carbapenem, cephalosporin, or other Î²lactam antibiotics. Severe medical or psychiatric condition or laboratory abnormality. Blood donation. 12 lead ECG abnormal.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>CAZ-AVI China phase I PK study</keyword>
</DOC>